Monday, February 18, 2019
News
NEWS HOME
PRN INDIA
Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
  SocialTwist Tell-a-Friend  
   

DARMSTADT, Germany, October 9, 2018 /PRNewswire/ --

Not intended for distribution in the USA, Canada or UK

ESMO Abstract #

Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; M7583: 1014PD; abituzumab: 487P; Erbitux (cetuximab): 124P, 484P, 509P, 493P, 521P, 510P, 481P, 486P, 1057P, 1108P, 1068P, 1064P, 1293P

  • First presentation of Phase III data for avelumab (plus axitinib) in previously untreated, advanced kidney cancer
  • New and updated data for bifunctional immunotherapy M7824
  • Results from Phase II trials for tepotinib, including in EGFR TKI-resistant NSCLC
  • Additional pipeline data feature abstracts for a further four innovative agents across multiple tumor types with a significant patient need

Merck, a leading science and technology company, today announced that new data from a variety of high-priority clinical development programs will be presented at the ESMO 2018 Congress (European Society for Medical Oncology Annual Meeting), October 19-23, 2018, Munich, Germany.

In the year that Merck celebrates its 350-year anniversary, abstracts at the congress represent a company record with eight therapeutic agents across 14 tumor types, reinforcing Merck's position at the forefront of clinical development in oncology.

"Our data at this year's European Society for Medical Oncology Congress expand our understanding of avelumab in renal cell carcinoma and other tumors, and demonstrate the headway we are making with our pipeline, including bifunctional immunotherapy M7824 and tepotinib," said Luciano Rossetti, Global Head of Research & Development for the Biopharma business of Merck. "We look forward to many more years of real and significant progress towards our vision of transforming the management and treatment of cancer."

Data from the Phase III study JAVELIN Renal 101, evaluating avelumab* in combination with axitinib, compared with sunitinib as initial therapy for patients with advanced renal cell carcinoma (RCC), will be presented for the first time during the Presidential Symposium at ESMO on Sunday, October 21, 2018 at 5:20 PM - 5:35 PM CEST. Avelumab is being jointly developed and commercialized with Pfizer. The results represent the first positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type, supporting Merck's interest in the potential use of avelumab in combination with currently approved therapies and novel agents. These results will be submitted for publication in a peer-reviewed journal. Other updates include new avelumab data in Merkel cell carcinoma (MCC) and advanced gastric or gastroesophageal junction (GEJ) cancer.

New data for M7824 will be presented from expansion cohorts of two ongoing Phase I clinical trials, including the first tumor-specific data for squamous cell carcinoma of the head and neck (SCCHN), biliary tract cancer, esophageal squamous cell carcinoma and esophageal adenocarcinoma. In addition, updated data for M7824 in patients with gastric cancer and non-small cell lung cancer (NSCLC) will be shared. M7824, discovered in-house at Merck, is an investigational bifunctional immunotherapy designed to combine a transforming growth factor β (TGF-β) trap by 'fusing' it with the anti-programmed death ligand-1 (PD-L1) mechanism. To date more than 650 patients with various types of solid tumors have been treated across the program with M7824 and the safety profile is consistent with that observed with other PD-1/PD-L1 inhibitors and previously described skin lesions (keratoacanthomas, SCC, hyperkeratosis) associated with TGF-β-inhibiting therapies.

Data for tepotinib** include results from three Phase II trials in epidermal growth factor receptor (EGFR) TKI-resistant NSCLC and advanced hepatocellular carcinoma, providing further evidence of this precision medicine's potential clinical activity in a range of tumors. Tepotinib, discovered in-house at Merck, is an investigational, oral MET inhibitor that is designed to selectively inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations or MET protein overexpression.

Additional pipeline abstracts feature updated data from Merck's comprehensive DNA damage response (DDR) portfolio. These include results from a Phase I trial investigating M6620 (formerly VX-970) in combination with gemcitabine in patients with advanced NSCLC, and combined data from two Phase I trials of DNA-dependent protein kinase inhibitor, M3814. Results will also be shared from a Phase I/II trial of M7583, a Bruton's TKI, in patients with B-cell malignancies, as well as a retrospective analysis of the Phase I/II Poseidon study investigating abituzumab in patients with metastatic colorectal cancer (mCRC).

Data to be presented at the congress for Erbitux will add to the growing body of real-world evidence supporting the therapy's role as a standard of care in RAS wild-type mCRC and first-line recurrent or metastatic SCCHN (R/M SCCHN), and for patients with locally advanced SCCHN (LA SCCHN) who may not be able to tolerate cisplatin-based regimens in full.

*Avelumab is under clinical investigation for the treatment of RCC, MCC, CRC, gastric and GEJ cancer, and has not been demonstrated to be safe and effective for these indications. There is no guarantee that avelumab will be approved for RCC, CRC, gastric or GEJ cancer by any health authority worldwide.

**Tepotinib is the recommended International Nonproprietary Name (INN) for the MET kinase inhibitor MSC2156119J. Tepotinib is currently under clinical investigation and not approved for any use anywhere in the world.

Tepotinib, M7824, M3814, M7583, M6620 and abituzumab are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication by any health authority worldwide.

Notes to Editors

Key Merck-supported abstracts slated for presentation are listed below. In addition, a number of investigator-sponsored studies have been accepted (not listed).


   
    Title                   Lead Author   Abstract #  Presentation       Location

                                                      Date / Time
                                                      (CEST)
    Avelumab
    Late-Breaking Abstracts
    JAVELIN Renal 101:      R Motzer      LBA6_PR     Sun, Oct 21,       Hall A2 -
    a randomized,                                     4:30 - 6:10 PM     Room 18
    phase 3 study of                                  (5:20 - 5:35 PM
    avelumab +                                        lecture time)
    axitinib vs                                      
    sunitinib as
    first-line
    treatment of
    advanced renal
    cell carcinoma                        
    (aRCC)    

    Poster Sessions
    Avelumab                T Doi         659P        Sun, Oct 21        Hall A3 -
    (anti-PD-L1) in                                   12:45 - 1:45 PM    Poster Area
    Japanese patients                                                    Networking Hub
    with advanced
    gastric or
    gastroesophageal
    junction cancer
    (GC/GEJC): updated
    results from the              
    phase 1b JAVELIN                                      
    Solid Tumor JPN                              
    trial                 
    Avelumab in             P Nathan      1290P       Sun, Oct 21,       Hall A3 -
    European patients                                 12:45 - 1:45 PM    Poster Area
    (pts) with                                                           Networking Hub
    metastatic Merkel
    cell carcinoma
    (mMCC): experience                       
    from an ad hoc                                        
    expanded access                         
    program (EAP)
    Cost-effectiveness      M Bharmal     1291P       Sun, Oct 21,       Hall A3 -
    (CE) of avelumab                                  12:45 - 1:45 PM    Poster Area
    vs standard care                                                     Networking Hub
    (SC) for the
    treatment of
    patients (pts)
    with metastatic                                           
    Merkel cell                                
    carcinoma (mMCC)  
    Responder analysis      SP D'Angelo   1282P       Sun, Oct 21,       Hall A3 -
    based on                                          12:45 - 1:45 PM    Poster Area
    patient-reported                                                     Networking Hub
    outcomes (PROs)
    and clinical
    endpoints (CEPs)
    in patients (pts)
    with metastatic
    Merkel cell                                     
    carcinoma (mMCC)                                        
    treated with                               
    avelumab          
    First-line (1L) or      UN                        Mon, Oct 22,       Hall A3 -
    second-line (2L)        Vaishampayan  877P        12:45 - 1:45 PM    Poster Area
    avelumab                                                             Networking Hub
    monotherapy in
    patients (pts)
    with advanced
    renal cell
    carcinoma (aRCC)
    enrolled in the 
    phase 1b JAVELIN 
    Solid Tumor trial 


   
    Title                         Lead Author   Abstract #  Presentation      Location
                                                            Date / Time
                                                            (CEST
    M7824 (TGF β-trap/anti-PD-L1)

    Proffered Paper Session
    M7824                         BC Cho        1048O       Mon, Oct 22,      ICM, Room
    (MSB0011359C), a                                        2:45 - 4:15 PM    14B
    bifunctional                                            (3:00 PM
    fusion protein                                          lecture time)
    targeting PD-L1
    and TGF-β, in
    patients (pts)
    with advanced                            
    SCCHN: results                                  
    from a phase 1                                   
    cohort                       
    Poster Sessions
    Updated results of            L Paz-Ares    1463P       Sat, Oct 20,      Hall A3 -
    M7824                                                   12:30 - 1:30 PM   Poster Area
    (MSB0011359C), a                                                          Networking Hub
    bifunctional
    fusion protein
    targeting TGF-β                                               
    and PD-L1, in                                                           
    second-line (2L)                                        
    NSCLC             
    Assessment of PD1/            T Mrowiec     1931P       Sun, Oct 21,      Hall A3 -
    PD-L1                                                   12:45 - 1:45 PM   Poster Area
    colocalization in                                                         Networking Hub
    hepatocellular
    carcinoma (HCC)
    using brightfield
    double labeling                            
    and quantitative                                 
    digital image                      
    analysis         
    M7824                         C Yoo         757P        Sun, Oct 21,      Hall A3 -
    (MSB0011359C), a                                        12:45 - 1:45 PM   Poster Area
    bifunctional                                                              Networking Hub
    fusion protein
    targeting PD-L1
    and TGF-β, in
    Asian patients
    with pretreated
    biliary tract
    cancer:  
    preliminary                                           
    results from a                         
    phase 1 trial     
    M7824                         B Tan          643P       Sun, Oct 21,      Hall A3 -
    (MSB0011359C), a                                        12:45 - 1:45 PM   Poster Area
    bifunctional                                                              Networking Hub
    fusion protein
    targeting PD-L1
    and TGF-β, in
    patients with
    post-platinum
    esophageal
    adenocarcinoma                                 
    (EAC): preliminary                                      
    results from a                            
    phase 1 cohort     
    Phase 1 study                 CC Lin         642P       Sun, Oct 21,      Hall A3 -
    results from an                                         12:45 - 1:45 PM   Poster Area
    esophageal                                                                Networking Hub
    squamous cell
    carcinoma (ESCC)
    cohort treated
    with M7824
    (MSB0011359C), a
    bifunctional
    fusion protein
    targeting
    transforming                                
    growth factor β                                     
    (TGF-β) and                           
    PD-L1             
    Updated results               YJ Bang        661P       Sun, Oct 21,      Hall A3 -
    from a phase 1                                          12:45 - 1:45 PM   Poster Area
    trial of M7824                                                            Networking Hub
    (MSB0011359C), a
    bifunctional
    fusion protein
    targeting PD-L1
    and TGF-β, in
    patients with                 
    pretreated                                            
    recurrent or                                           
    refractory gastric                                
    cancer            


   
    Title                   Lead Author  Abstract #  Presentation      Location
                                                     Date / Time
                                                     (CEST)
    Tepotinib
    Proffered Paper Session
    Phase 2 study of        YL Wu        1377O       Fri, Oct 19,      Hall A2,
    tepotinib +                                      4:00 - 5:30 PM    Room 18
    gefitinib                                        (4:51 PM
    (TEP+GEF) in                                     lecture time)
    MET-positive
    (MET+)/epidermal
    growth factor
    receptor                           
    (EGFR)-mutant (MT)                   
    non-small lung                           
    cancer (NSCLC)   
    Poster Discussion
    Phase 2 trial of         BY Ryoo     621PD       Fri, Oct 19,      Hall B3,
    tepotinib vs                                     3:45 - 5:30 PM    Room 21
    sorafenib in Asian                               (4:25 PM
    patients (pts)                                   lecture time)
    with advanced                            
    hepatocellular                            
    carcinoma (HCC)  
    Poster Session
    Phase 2 efficacy         T Decaens   698P        Sun, Oct 21,      Hall A3 -
    and safety data                                  12:45 - 1:45 PM   Poster Area
    for the MET                                                        Networking Hub
    inhibitor
    tepotinib in
    patients (pts)
    with                                  
    sorafenib-treated                                  
    advanced                                                
    hepatocellular                                          
    carcinoma (HCC)   


   
    Title              Lead Author  Abstract #  Presentation     Location
                                                Date / Time
                                                (CEST)         
    M6620
    Poster Session
    Phase I dose       R Plummer    1437P       Sat, Oct 20,     Hall A3 -
    expansion data for                          12:30 - 1:30 PM  Poster Area
    M6620 (formerly                                              Networking Hub
    VX-970), a
    first-in-class ATR
    inhibitor,
    combined with
    gemcitabine (Gem)
    in patients (pts)
    with advanced   
    non-small cell 
    lung cancer                           
    (NSCLC)     


   
    Title              Lead Author     Abstract #  Presentation     Location
                                                   Date / Time
                                                   (CEST)
    M3814
    Poster Session
    Safety, clinical   M Mau-Sørensen  1845P       Sat, Oct 20,     Hall A3 -
    activity and                                   12:30 - 1:30 PM  Poster Area
    pharmacological                                                 Networking Hub
    biomarker
    evaluation of the
    DNA-dependent
    protein kinase
    (DNAPK) inhibitor
    M3814: results                                           
    from two phase I  
    trials              


   
    Title              Lead Author   Abstract #  Presentation    Location
                                                 Date / Time
                                                 (CEST)
    M7583
    Poster Session
    Phase I/II, first  W Jurczak     1014PD      Sun, Oct 21,    Hall B3 -
    in human trial                               4:30 - 5:45 PM  Room 21
    with M7583, a
    Bruton's tyrosine
    kinase inhibitor
    (BTKi), in
    patients with B
    cell malignancies      



   
    Title              Lead Author   Abstract #  Presentation      Location
                                                 Date / Time
                                                 (CEST)
    Abituzumab
    Poster session
    Patient selection   R Laeufle    487P        Sun, Oct 21,      Hall A3 -
    for targeting                                12:45 - 1:45 PM   Poster Area
    integrin with                                                  Networking Hub
    abituzumab in
    patients with
    metastatic
    colorectal cancer
    (mCRC). A
    retrospective
    analysis of the                                      
    randomized phase                                        
    I/II Poseidon                            
    study            


   
    Title              Lead Author        Abstract #  Presentation       Location
                                                      Date / Time
                                                      (CEST)  
    Erbitux
    Poster Sessions
    Association of     L Miller-Phillips  124P        Sat, Oct 20,       Hall A3 -
    microRNA-21                                       12:30 - 1:30 PM    Poster Area
    (miR-21) with                                                        Networking Hub
    efficacy of
    cetuximab (cet)
    and bevacizumab
    (bev) in patients
    with metastatic
    colorectal cancer                                    
    (mCRC) within the
    FIRE-3 study (AIO 
    KRK-0306)         
    Retrospective RAS   A Sobrero         484P        Sun, Oct 21,       Hall A3 -
    analysis of the                                   12:45 - 1:45 PM    Poster Area
    EPIC trial:                                                          Networking Hub
    Cetuximab plus
    irinotecan versus
    irinotecan alone
    in patients with
    third- and                           
    further-line                                           
    metastatic                                
    colorectal cancer
    Factors             DP Modest         509P        Sun, Oct 21,       Hall A3 -
    influencing                                       12:45 - 1:45 PM    Poster Area
    conversion to                                                        Networking Hub
    resectability and
    survival after
    resection of
    metastases in RAS
    WT metastatic
    colorectal cancer                                      
    (mCRC): analysis                                           
    of FIRE-3-                                  
    AIOKRK0306        
    Initial report of   E Oki             493P        Sun, Oct 21,       Hall A3 -
    a phase I/II study                                12:45 - 1:45 PM    Poster Area
    of S-1 and                                                           Networking Hub
    irinotecan (IRIS)
    in combination
    with cetuximab in
    patients with                                          
    wild-type (wt) RAS                                         
    metastatic                            
    colorectal cancer 
    miR-31 as a         Y Gaston-Mathé    521P        Sun, Oct 21,       Hall A3 -
    prognostic and                                    12:45 - 1:45 PM    Poster Area
    predictive marker                                                    Networking Hub
    of disease-free
    survival (DFS) in
    resected stage III
    colon cancer: a                             
    retrospective                                           
    analysis of the  
    PETACC-8 trial    
    Targeted therapies  BC Xing           510P        Sun, Oct 21,       Hall A3 -
    in conversion                                     12:45 - 1:45 PM    Poster Area
    therapy in mCRC: A                                                   Networking Hub
    systematic review 
    and meta-analysis 
    Phase II study of   H Osawa           481P        Sun, Oct 21,       Hall A3 -
    cetuximab                                         12:45 - 1:45 PM    Poster Area
    rechallenge in                                                       Networking Hub
    patients with RAS
    wild-type
    metastatic          
    colorectal cancer:                               
    E-rechallenge           
    trial            
    Prospective         X García-Albéniz  486P        Sun, Oct 21,       Hall A3 -
    biomarker study in                                12:45 - 1:45 PM    Poster Area
    advanced RAS                                                         Networking Hub
    wild-type                   
    colorectal cancer.
    POSIBA trial.     
    (GEMCAD 10-02)    
    Cetuximab +         C Le Tourneau     1057P       Sun, Oct 21,       Hall A3 -
    platinum-based                                    12:45 - 1:45 PM    Poster Area
    therapy (PBT) as a                                                   Networking Hub
    first-line
    treatment for
    patients with
    recurrent/metastat
    ic squamous cell
    carcinoma of the
    head and neck (R/M                                            
    SCCHN): an                                                        
    observational                                      
    study (ENCORE)      
    Can concomitant     J Dunst           1108P        Sun, Oct 21,      Hall A3 -    
    diseases predict                                   12:45 - 1:45 PM   Poster Area
    the compliance                                                       Networking Hub
    with cisplatin
    plus RT in
    patients with
    locally advanced
    squamous cell
    carcinoma of the
    head and neck (LA
    SCCHN)? An
    exploratory                                       
    endpoint analysis                                    
    of the COMPLY                               
    trial             
    Cetuximab in        JC Ham            1068P        Sun, Oct 21,      Hall A3 -
    combination with                                   12:45 - 1:45 PM   Poster Area
    methotrexate (MTX)                                                   Networking Hub
    as first-line
    treatment in
    recurrent or
    metastatic (R/M)
    squamous cell
    carcinoma of the
    head and neck
    (SCCHN), a phase
    Ib - randomized                                    
    phase II study                                        
    versus single                               
    agent MTX         
    Cetuximab in        M Hecht           1064P         Sun, Oct 21,     Hall A3 -  
    combination with                                    12:45 - 1:45 PM  Poster Area
    platinum-based                                                       Networking Hub
    chemotherapy or
    radiotherapy in
    patients with
    recurrent and/or
    metastatic SSCHN
    in clinical
    routine: Updated                                    
    interim results of                                        
    the prospective                             
    SOCCER study      
    Cetuximab in        F Peyrade         1293P          Sun, Oct 21,    Hall A3 -
    patients with                                        12:45 - 1:45 PM Poster Area
    unresectable                                                         Networking Hu
    cutaneous squamous
    cell carcinoma is                                    
    safe and effective                                    
    - A real-life                               
    analysis         

About Avelumab

Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.[1]-[3] Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.[3]-[5] In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.

Avelumab is currently being evaluated in the JAVELIN clinical development program, which involves at least 30 clinical programs, including seven Phase III trials, and more than 8,600 patients across more than 15 different tumor types. For a comprehensive list of all avelumab trials, please visit clinicaltrials.gov.

Approved Indications in the US

The US Food and Drug Administration (FDA) granted accelerated approval for avelumab (BAVENCIO ) for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information from the US FDA Approved Label

The warnings and precautions for BAVENCIO include immune-mediated adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction, and other adverse reactions), infusion-related reactions and embryo-fetal toxicity.

Common adverse reactions (reported in at least 20% of patients) in patients treated with BAVENCIO for mMCC and patients with locally advanced or mUC include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash.

About M7824

M7824 is an investigational bifunctional immunotherapy that is designed to bring together a TGF-β trap and 'fuse' it with the anti-PD-L1 mechanism. M7824 is designed to simultaneously block the two immunosuppressive pathways - targeting both pathways aims to control tumor growth by potentially restoring and enhancing anti-tumor responses. M7824 is currently in Phase I studies for solid tumors.

About Tepotinib

Tepotinib (MSC2156119J) is an investigational, oral MET inhibitor that is thought to inhibit oncogenic MET receptor signaling caused by MET (gene) alterations, including both MET exon 14 skipping mutations and MET amplifications, or MET protein overexpression. It is a precision medicine and is designed to have a highly selective mechanism of action.

About M6620

M6620 (previously known as VX-970) is an investigational small-molecule thought to inhibit ataxia telangiectasia and Rad3-related protein (ATR). ATR is believed to be a key sensor for DNA damage, activating the DNA damage checkpoint and leading to cell cycle arrest. Inhibition of ATR could potentially enhance the efficacy of DNA-damaging agents, but is also being investigated as a monotherapy against tumors with high levels of replication stress induced by overexpression of oncogenes.

About M3814

M3814 is an investigational small-molecule which is thought to inhibit DNA-dependent protein kinase (DNA-PK). DNA-PK is a key enzyme for non-homologous end-joining (NHEJ), an important DNA double-strand break (DSB) repair pathway. Clinical studies investigating combinations of M3814 with other commonly used DNA-damaging agents such as radiotherapy and chemotherapy are underway.

About M7583

M7583 is an investigational therapy that is thought to be a highly selective covalent inhibitor of Bruton's tyrosine kinase (BTKi) designed to minimize off-target effects.

About Abituzumab

Abituzumab is an investigational pan-αν integrin inhibiting monoclonal antibody thought to show activity against αvβ1, 3, 5, 6 and 8 integrin heterodimers. Merck entered into a development agreement with the SFJ Pharmaceuticals Group for abituzumab in metastatic colorectal cancer (mCRC). This collaboration will allow Merck and SFJ to develop the potential of abituzumab in a targeted way, focusing on a patient population that may benefit from the treatment the most.

About Erbitux (cetuximab)

Erbitux is a IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, Erbitux also targets cytotoxic immune effector cells towards EGFR expressing tumor cells (antibody dependent cell-mediated cytotoxicity, ADCC).

The most commonly reported side effect with Erbitux is an acne-like skin rash. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.

Erbitux has already obtained market authorization in over 100 countries world-wide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck licensed the right to market Erbitux, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

References

  1. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 2014;21:231-7.
  2. Dahan R et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 2015;28:285-95.
  3. Boyerinas B et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015;3:1148-57.
  4. Kohrt HE et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012;4:511-27.
  5. Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther 2017;17:515-23.

(Logo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg )

More News by PR Newswire India

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Kochava Announces Latest Enhancements to IdentityLink, Giving Marketers a Clearer View of Their User Journeys

Battery Manufacturers to Integrate Energy Intelligence into Storage Systems to Tap Growth Opportunities

EB-5 February 15th Update: What Investors can Expect for the Future of EB-5

Rivian Announces $700M Investment Round Led By Amazon

OPPO's Gradient Design and Panoramic Screen Redefine Smartphone Experiences

JTI Awarded Top Employer for the 5th Consecutive Year

MORE - A Unique Hospitalisation Health Insurance Plan From Reliance Health Insurance

Schneider Electric Puts Control of Power distribution in Digital Devices; Launches Masterpact MTZ in India

Cyient Recognized as a "Major Contender" in Everest Group's PEAK Matrix™: Medical Device Engineering Services Assessment 2019

TÜV SÜD Receives Accreditation From Quality Council of India to Certify Ready Mixed Concrete Plants

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

Global Business Summit to Address Challenges of a World in Transition

Sterlite Power Forays Into Grid Connected Battery Storage

Firefox for iOS Amps Up Private Browsing and More

Australia's First Kafnu To Open in Sydney

Singular Announces Global-First Cross-Device, Cross-Platform ROI Analytics

FastMatch And Former CEO, Dmitri Galinov, Confirm Settlement Agreement

The Stars Group Recognized With Industry Honors

Prozone Intu's Consolidated Revenues up 20% y-o-y to INR 33.9 Crore

New Milestone Reached With More Than 500 Dolby Atmos Screens Installed and 500 Dolby Atmos Titles Released in India

Thailand's Promotion of Advanced Technology and Eco-system Development Enables Local Producers to Fly Higher

OPPO is Set to Redefine its Design Statement With its #OPPOF11Pro Campaign

TÜV SÜD Showcases its SFDA and Halal Certification Capabilities at Gulfood

Perpule Launches UltraPOS, an Omni-channel Retail Solution, With Marquee Customers

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens' FibroScan®, Imposes Damages & Orders Halt to Manufacturing and Sales

UST Global Launches True Private Cloud Platform 'UST FORTUNA'

IIIT-Hyderabad Opens Admissions to its Undergraduate Programs for the Academic Year 2019-20

Saksoft Limited: 9MFY19 Revenues at Rs. 264 Crs, a Growth of 27% Y-o-Y

Mr. Binish Chudgar Wins the EY Entrepreneur of the Year 2018 Award in Life Sciences & Healthcare Category

Strata Celebrates Grand Opening of New Manufacturing Facility in India

MEIL's Innovation in Irrigation

ResellerClub Turns 13, Celebrates With Big Birthday Bash Sale on Hosting and Domains

Orthonova Hospital Performs Hip Replacement Surgery on 110 Years Old Lady

Frost & Sullivan Publishes Q1 2019 Update on Oramed Pharmaceuticals Inc.

16 Longevity Scientists Have A Valentine's Day Message For The World

Aon Releases 2019 Cyber Security Risk Report: "What's Now and What's Next"

Io-Tahoe releases enhanced Smart Data Discovery solution, with PII and Sensitive Data Discovery capability, enabling compliance with the California Consumer Privacy Act (CCPA)

Vidsys Recognized by Frost & Sullivan for its Comprehensive Converged Security Information Management System, RiskShield Enterprise

Prepare your Business for Digital Era to Transform Industrial Valves and Actuators Market

Auto Insurers Seize Growth Opportunities by Offering Financial and Insurance Tools over Digital Platforms

Suning.com Announced the Establishment of Department Store Group to Accelerate Its Full-Scenarios Development in Omni-channel Smart Retail

Medvarsity Online Ltd. Awarded as the Best Medical Institute in India at 9th Indian Education Awards 2019

Tableau Expands Data Prep Capabilities with Tableau Prep Conductor

JET8 Launches World's First Social Wallet

India Pharma Week 2018: Strengthening the Pharma Ecosystem in the Power Corridors of the North

Tableau Releases Ask Data, A New and Intuitive Way to Analyze Data With Natural Language

WCG Releases New Theme Song, Beyond the Game (Steve Aoki Remix)

FLAME University's Entrepreneurship Centre all Set to Catalyze the Indian Startup Ecosystem

Mumbai Recorded Gross Absorption of 2.1 Million sq ft in Q4 2018, Registering an Increase of 5.7% QoQ: Colliers International India

Kolkata Recorded Overall Absorption of 215,500 sq ft in Q4 2018: Kolkata Recorded Overall Absorption of 215,500 sq ft in Q4 2018: Colliers International India

IHG® Welcomes Six Senses Hotels Resorts Spas to its Family of Brands

Hyderabad Witnessed Gross Absorption of 6.8 Million sq ft in 2018, Highest in the Last Eight Years: Colliers International India

Letstrack CEO Named as India's Inspirational Leader by WCRC

Chennai Recorded 3.9 Million sq. ft. of Gross Leasing in 2018, a Decline of 18% From the Previous Year: Colliers International India

Fractal Analytics Hosts its First Conference in London to Help FTSE 250's Solve Problems at Scale Through AI, Engineering and Design

Manpasand Beverages Ltd Announces Q3 & 9MFY19 Results

HITLAB Innovators Summit: India Assembles Leaders Across Healthcare Ecosystem to Bring Meaningful Innovation to Over a Billion Lives

VARTA Applauded by Frost & Sullivan for its Smart, Scalable Residential Battery Storage Systems

India Biggest Obstacle Running Event, Maruti Suzuki Arena Devils Circuit - Jaipur Edition, Concludes

Intuition Systems Introduces Cloud-based IVEPOS Enterprise® With Multi-store Management for Large Restaurants and Retail Enterprises With up to 100 Stores

Essence wins integrated media duties for online higher education platform UpGrad in India

Pennar Industries Reports 34% y-o-y Increase in Q3 FY2019 Standalone PAT at INR 11.5 crore

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to treat patient in study to evaluate balloon ablation catheter for treating Atrial Fibrillation

Novartis leverages digital transformation to address most pressing health challenges in Asia

Smiths Detection to greatly improve security and passenger experience at Northern Territory airports

IBM Announces Additional $25 Million Investment to Put Technology to Work Saving Lives

Jay Lang Appointed President Of Charkit Chemical

Colt Data Centre Services Appoints Sujeet Deshpande as New Country Head in India

Largest Study Of Mobile Ad Networks Ranks Facebook, Google, Snap, Twitter, Unity … And New Players

Frost & Sullivan Publishes Immediate Report on BiolineRx

IBM Unveils New Offerings for Faster and More Secured Path to Hybrid Cloud

IBM Watson Now Available Anywhere

CGTN America Receives 28 Awards in The White House News Photographers Association 2019 'Eyes of History' Video Contest

Adjust Raises the Bar With a New Industry Standard in the Global Fight Against Mobile Ad Fraud

Blockchain, Augmented Reality and Virtual Reality Highlighted as Emerging Trends at Frost & Sullivan's 2019 ICT Predictions Road Show

GTPL Hathway's Consolidated Q3 FY2019 Revenue at ₹ 3,199 Million, up 13% Y-o-Y

Firmenich CEO in Global Top 100 C-Suite Ranking

IBM Commended by Frost & Sullivan for Its Strong Managed Service Offerings in the Business-critical ERP Services Market

Loadsmart's Automated Freight Brokerage System Awarded Company of the Year by Frost & Sullivan

Kore.ai Earns Acclaim from Frost & Sullivan for its Visionary Conversational AI Platform that Helps Create Intelligent Financial Enterprises

Bill and Melinda Gates Release 2019 Annual Letter: "Things We Didn't See Coming"

Avon appoints Kay Nemoto as Chief Strategy and HR Officer to drive transformation

CORRECTION - Indo Amines Limited: Indo Amines Limited Declares a Robust Financial Growth Revenue at Rs. 120.16 Crs; EBITDA Stood at Rs. 16.09 Crs; PAT Reported at Rs. 6.88 Crs

Microland Positioned as a Major Contender in Everest Group's Cloud Enablement Services PEAK Matrix Assessment

Lincoln Electric System Partners with energyOrbit to Automate Management of Energy Efficiency Programs

Organica Water Selected for the 2019 Global Cleantech 100 list

Digital Transformation to Advance Global Airlines' Growth Prospects

GO GABA Founder Launches Campaign Iwantmybusinessback.com to Raise Awareness for Entrepreneurs

UNISOC Collaborates with Google to Carry out GMS Certification, Shortening the Time to Market for Mobile Devices

Singing app of Spotlite employs robots as judge for online games

SPJIMR’s PGMPW Receives AMBA’s ‘MBA Innovation Award’

/Disregard Release: S.P. Jain Institute of Management & Research: SPJIMR’s PGPMW Receives AMBA’s ‘MBA Innovation Award’/

Falabella Group and ThoughtWorks Partner to Accelerate the Digital Commerce Journey of Latin America’s Leading Integrated Retail Brand

Discover The World 'On The Go' With SOTC's Newly Launched Portal

A New Year, A New Beginning, A New Office for 42Gears

InComm Launches Google Play Gift Cards in Malaysia

DigitalBerge, The #1 SEO Company in Delhi NCR, Launches its Personal Branding Services

AACSB's Accreditation Quality Management System Achieves ISO 9001:2015

HMC Launches Centara Privilege - Providing Members in Thailand with Personalized Benefits and Recognition

SBI Neo Financial Services and AntWorks™ Announce Joint Venture to Provide Intelligent Automation to ASEAN Market Through SBI Antworks Asia

Growatt Donates Inverter to Indore Cancer Foundation's Rooftop Solar Plant Project

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

IBM Chairman, President And CEO Ginni Rometty To Keynote IBM Think 2019

The XXI Habanos Festival Kicks Off

Frost & Sullivan Webinar Explores What's Driving the Global Automotive Industry in 2019

National Geographic and Sky Ocean Ventures Launch Global Search for Alternatives to Single-Use Plastics

Prime Minister Shri Narendra Modi Laid Foundation Stone for Bio-refinery Project in Assam, a Collaboration of NRL, Fortum and Chempolis

SPJIMR’s PGPMW Receives AMBA’s ‘MBA Innovation Award’

Use of Big Data Technology in Cybersecurity Solutions to Help Enterprises Proactively Prevent Breaches

Viamedici Acclaimed by Frost & Sullivan for its Comprehensive Viamedici EPIM Platform for Data Management

Indo Amines Limited Declares a Robust Financial Growth Revenue at Rs. 120.16 Crs; EBITDA Stood at Rs. 16.09 Crs; PAT Reported at Rs. 6.88 Crs

"Thailand Investment Year" Sets to Accelerate Economic Shift and Boost Economic Growth

Johnson & Johnson India Shows Support to the LGBTQ+ Community, Participates in the Queer Azaadi Mumbai (QAM) Pride March

DLF Shopping Malls Celebrate a Decade of Retail Excellence

Privatisation a catalyst to unlock Eskom's true value potential

PIOUS AYURVEDA Announces Release of its Revolutionary Book 'SAVE YOUR HEADMASTER'

Coconics Unveils its First Range of Laptops at the Electronics Manufacturing Summit 2019 in Delhi

Kirti Mandir in Barsana Opens in a Grand and Historical Opening Ceremony

Flamingo Transworld Scoops 8 Awards at the Gujarat Tourism Awards 2018

IMA Releases Enhanced Management Accounting Competency Framework for Professionals in the Digital Age

Dr Batra's Homeopathy Offers Free Preventive Doses for Swine Flu Across Jaipur, Delhi, Chandigarh, Ahmedabad and Hyderabad

Red Box Announces Partnership With Global Relay, Expanding Its Financial Services Ecosystem and Compliance Offering

NirvanaBeing Announces a 20% Discount on Mace Pepper Spray

Tufin Appoints Michael Bosnar to the Position of Vice President of Asia-Pacific Sales

BATTERY JAPAN 2019: Solid-state battery and EV battery imminently set for commercialisation

WIND EXPO 2019: Industry leaders gather in Japan at the dawn of emerging offshore wind power

Japan's business continues to look bright at PV EXPO & PV SYSTEM EXPO 2019

STRATACACHE Centralizes Asia-­Pacific Operations in New Singapore Headquarters

Japan Rock Band CHAI Partners with PicsArt, #1 Photo & Video-Editing App, to Creatively Engage with Fans

Vivo Unveils New Visual Brand Identity

The Sunhak Peace Prize for 2019 Convened in Seoul Awarding Akinwumi Ayodeji Adesina & Waris Dirie

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
One jawan injured in encounter with Naxa...
Ahead of polls, YSRCP chief Jagan Reddy ...
J-K: Encounter between security forces a...
Odisha CM lays foundation stone for Canc...
Hyderabad gets its first Trompe-loeil a...
2 Youth Cong workers hacked to death in ...
More...    
 
 Top Stories
Poland PM cancels Israel trip after... 
9 dead in Boko Haram attack in Nige... 
Odisha CM lays foundation stone for... 
Mike Posner stays silent to preserv... 
Iran summons Pak envoy over suicide... 
J-K: Encounter between security for... 
Assad says Syrian constitution not ... 
Ahead of polls, YSRCP chief Jagan R...